文献速递头颈外科

基于回顾性生存分析的头颈癌单发和多发肺转移SBRT患者新型预后评分(HAMP)

A novel prognostic score (HAMP) for head and neck cancer patients with single and multiple SBRT-treated lung metastases derived from retrospective analyses of survival outcome.
PubMed 文献 · Head Neck · 2024-08-08

本回顾性研究纳入2009至2023年59例因头颈癌肺转移(共118个转移灶)接受立体定向体部放疗(SBRT)的患者,基于组织学、年龄、转移灶数目和体能状态构建HAMP预后评分。总分13–24分,≤18分为高危组,≥19分为低危组;低危组中位无进展生存期(23.8 vs 5.5个月,p<0.001)和总生存期(61.3 vs 16.4个月,p<0.001)均显著长于高危组。

要点

  • HAMP评分由组织学、年龄、转移灶数目和首次SBRT时体能状态构成,总分13–24分。
  • ≤18分为高危组,≥19分为低危组。
  • 低危组中位PFS和OS均显著长于高危组。

核心结论

  • HAMP评分可能是一个便捷工具,有助于个体化治疗决策和适当随访。
  • 该评分的准确性和可靠性需在前瞻性研究中进一步评估。

研究设计与样本

  • 回顾性研究,纳入2009至2023年59例头颈癌患者,共118个肺转移灶接受SBRT治疗。
  • 分析与无进展生存期和总生存期相关的因素,并纳入预后评分系统。

主要发现

  • 预后因素包括组织学、年龄、转移灶数目和首次SBRT时体能状态,根据与PFS和OS的相关强度赋予不同权重。
  • HAMP总分范围为13至24分,高危组为≤18分,低危组为≥19分。
  • 低危组中位PFS为23.8个月,高危组为5.5个月(p < 0.001)。
  • 低危组中位OS为61.3个月,高危组为16.4个月(p < 0.001)。

关键数值与推荐

  • HAMP评分总分13–24分;高危组≤18分,低危组≥19分。
  • 低危组中位PFS 23.8个月 vs 高危组5.5个月(p < 0.001)。
  • 低危组中位OS 61.3个月 vs 高危组16.4个月(p < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We report on the characterization and introduction of a novel prognostic score for patients undergoing stereotactic body radiotherapy (SBRT) for the treatment of single and multiple pulmonary metastases (PMs) derived from head and neck cancer (HNC). METHODS: In this retrospective study, we examined selected factors associated with progression-free survival (PFS) and overall survival (OS) among 59 patients with HNC treated with SBRT for a total of 118 PMs, between 2009 and 2023. Factors related to survival were included in the prognostic scoring system. RESULTS: Prognostic factors including histology, age, number of metastases, and performance status at first SBRT were weighted differently depending on the strength of correlation to PFS and OS. Total prognostic scores (HAMP) ranged from 13 to 24 points, with a cut-off total score of ≤18 scoring points for patients in a high-risk (HR) subcohort, and of ≥19 scoring points for patients in a low-risk group (LR). Median PFS (23.8 vs. 5.5 months, p < 0.001) and OS (61.3 vs. 16.4 months, p < 0.001) were significantly longer in the low-risk group compared to the high-risk group. CONCLUSION: The HAMP score might be a convenient tool to facilitate individualized treatment decisions and appropriate follow-up. The accuracy and reliability of the score requires further evaluation in prospective studies.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Vorbach SM, Seppi T, Sarcletti MP, et al. A novel prognostic score (HAMP) for head and neck cancer patients with single and multiple SBRT-treated lung metastases derived from retrospective analyses of survival outcome. Head Neck. 2024. PMID: 39114975. doi:10.1002/hed.27913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。